MAPT and Alzheimer disease: Given the impact of FK506 on tau pathology (Yoshiyama et al., 2007), an alternative immunosuppression regimen was used for 3xTg‐AD mice that target the T‐cell costimulatory receptors LFA‐1, CD40L, and CTLA‐4 (Pearl et al., 2011).